Nucleophilic activation of a tetra-substituted mitomycin cyclic bis- disulfide

Chemical and Pharmaceutical Bulletin

Volumn 57, Issue 2, 2009, Pages 149-157

  Lee, Sang Hyup ^a,b   Kohn, Harold ^a,b  

^a Duksung Women's University   (South Korea)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Disulfide; DNA interstrand cross link; Mitomycin; Nucleophilic activation

Indexed keywords

7 N [2 [[2 (GAMMA GLUTAMYLAMINO)ETHYL]DITHIO]ETHYL]MITOMYCIN C; 7 N,7' N' (1'',2'',9'',10'' TETRATHIACYCLOHEXADECANYL 3'',8'',11'',16'' TETRAMETHYLENYL)TETRAKISMITOMYCIN C; 7 N,7' N' (2'',7'' DIHYDROXY 1'',8'' OCTANEDIYL)TETRAKISMITOMYCIN C; CARBON; DIMER; DISULFIDE; MITOMYCIN C; MITOMYCIN C DERIVATIVE; NUCLEOPHILE; UNCLASSIFIED DRUG;

ACIDITY; ARTICLE; CANCER CELL CULTURE; CULTURE MEDIUM; DNA CROSS LINKING; DRUG ACTIVATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; REACTION ANALYSIS; REDUCTION; STRUCTURE ANALYSIS;

ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CROSS-LINKING REAGENTS; DNA; DNA ADDUCTS; DRUG DESIGN; ELECTROPHORESIS, AGAR GEL; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; METHANOL; MITOMYCIN; SPECTROPHOTOMETRY, ULTRAVIOLET; SULFIDES;

EID: 61449110167     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.57.149     Document Type: Article

References (40)

1. Carter S. K., Crooke S. T., "Mitomycin C, Current Status and New Developments," Academic Press, New York, 1979.
2. Iyer V N., Szybalski W., Science, 145, 45-58 (1964).
3. Szybalski W., Iyer V. N., "Antibiotics. Mechanism of Action," Vol. 1, ed. by Gottlieb D., Shaw P. D., Springer-Verlag, New York, 1967, pp. 211-245.
4. Moore H. W., Czerniak R., Med. Res. Rev., 1, 249-280 (1981).
5. Hornemann U., Keller P. J., Kozlowski J. F., J. Am. Chem. Soc., 101, 7121-7124 (1979).
6. Keyes S. R., Loomis R., DiGiovanna M. P., Pritsos C. A., Rockwee S., Sartorelli A. C., Cancer Commun., 3, 351-356 (1991).
7. Ramos L. A., Lipman R., Tomasz M., Basu A. K., Proc. Am. Assoc. Cancer Res., 38, 182 (1997).
8. Tomasz M., Palom Y., Am. Pharmacol. Ther., 76, 73-87 (1997).
9. Kono M., Saitoh Y., Kasai M., Sato A., Shirahata K., Morimoto M., Ashizawa T., Chem. Pharm. Bull., 37, 1128-1130 (1989).
10. Vyas D. M., Chiang Y., Benigni D., Rose W. C., Brander W. T., "Recent Advances in Chemotherapy, Anticancer Section," ed. by Ishigami J., University of Tokyo Press, Tokyo, 1985, pp. 485-486.
11. Tsuruo T., Sudo Y., Asami N., Inaba M., Morimoto M., Cancer Chemother. Pharmacol., 27, 89-93 (1990).
12. Morimoto M., Ashizawa T., Ohno H., Azuma M., Kobayashi E., Okabe M., Gomi K., Kono M., Saitoh Y., Arai H., Sato A., Kasai M., Tsuruo T., Cancer Res., 51, 110-115 (1991).
13. Kobayashi E., Okabe M., Kono M., Arai H., Kasai M., Gomi K., Lee J.-H., Inaba M., Tsuruo T., Cancer Chemother. Pharmacol., 32, 20-24 (1993).
14. He Q.-Y., Maruenda H., Tomasz M., J. Am. Chem. Soc., 116, 9349- 9350 (1994).
15. Kohn H., Wang S., Tetrahedron Lett., 37, 2337-2340 (1996).
16. Wang S., Kohn H., J. Med. Chem., 42, 788-790 (1999).
17. Na Y., Wang S., Kohn H., J. Am. Chem. Soc., 124, 4666-4677 (2002).
18. Masters J. R. W., Know R. J., Hartley J. A., Kelland L. R., Hendricks H. R., Conners T., Biochem. Pharmacol., 53, 279-285 (1997).
19. McAdam S. R., Knox R. J., Hartley J. A., Masters J. R. W., Biochem. Pharmacol., 55, 1777-1783 (1998).
20. Rajaski S. R., Williams R. M., Chem. Rev., 98, 2723-2795 (1998).
21. Lee S. H., Kohn H., Org. Biomol. Chem., 3, 471-482 (2005), and references therein.
22. Na Y., Li V.-S., Nakanishi Y., Bastow K. F., Kohn H., J. Med. Chem., 44, 3453-3462 (2001).
23. Paz M. M., Kumar G. S., Glover M., Waring M. J., Tomasz M., J. Med. Chem., 47, 3308-3319 (2004).
24. Lee S. H., Brodnick R. L., Glish G. L., Kohn H., Tetrahedron, 61, 1749-1754 (2005).
25. Steven C. L., Taylor K. G., Munk M. E., Marshall W. S., Noll K., Shah G. D., Shah L. G., Uzu K., J. Med. Chem., 8, 1-10 (1965).
26. Tomasz M., Lipman R., J. Am. Chem. Soc., 101, 6063-6067 (1979).
27. McClelland R. A., Lam K., J. Am. Chem. Soc., 107, 5182-5186 (1985).
28. Lee S. H., Kohn H., J. Am. Chem. Soc., 126, 4281-1292 (2004).
29. Kobayashi S., Ushiki J., Takai K., Okumura S., Kono M., Kasai M., Gomi K., Morimoto M., Ueno H., Hirata T., Cancer Chemother. Pharmacol., 32, 143-150 (1993).
30. Yasuzawa T., Tomer K. B., Bioconjug. Chem., 8, 391-399 (1997).
31. Wang S., Kohn H., J. Org. Chem., 62, 5404-5412 (1997).
32. Hata T., Sano Y., Sugawara R., Matsomae A., Kanamori K., Shima T., Hosha T., J. Antibiot., 9, 141-146 (1956).
33. Compound 16 has 8 stereocenters that can lead to 256 possible di- astereomers not considering mirror image isomers.
34. Hong Y. P., Kohn H., J. Am. Chem. Soc., 113, 4634-4644 (1991).
35. Han I., Kohn H., J. Org. Chem., 56, 4648-1653 (1991).
36. R=33.5- 36.8 min (Fig. 1a)) with these reaction mixtures did not conclusively identify this product.
37. Lee S. H., Kohn H., Heterocycles, 60, 47-56 (2003).
38. Cech T. R., Biochemistry, 20, 1431-1437 (1981).
39. Tepe J. J., Williams R. M., J. Am. Chem. Soc., 121, 2951-2955 (1999).
40. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Viotica D., Warren J. T., Bokesch H., Kenny S., Boyd M. R., J. Natl. Cancer Inst., 82, 1107-1112 (1990).